Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6466 to 6480 of 7710 results

  1. Vandetanib for the second line treatment of non-small cell lung cancer [ID46]

    Discontinued [GID-TAG405]

    Technology appraisal guidance
    Discontinued

  2. Erlotinib in combination with bevacizumab for the maintenance treatment of advanced or metastatic non-small cell lung cancer [ID44]

    Discontinued [GID-TA11206]

    Technology appraisal guidance
    Discontinued

  3. Erlotinib in combination with bevacizumab for the second line treatment of advanced or metastatic non-small cell lung cancer [ID43]

    Discontinued [GID-TA11207]

    Technology appraisal guidance
    Discontinued

  4. Nivolumab for treating relapsed or refractory diffuse large B-cell lymphoma [ID986]

    Discontinued [GID-TA10140]

    Technology appraisal guidance
    Discontinued

  5. Eryaspase with chemotherapy for previously treated advanced or metastatic pancreatic cancer [ID3781]

    Discontinued [GID-TA10637]

    Technology appraisal guidance
    Discontinued

  6. Zio XT for detecting cardiac arrhythmias

    In development [GID-MT591] Expected publication date: TBC

    Medical technologies guidance
    In development

  7. Lifitegrast for treating dry eye disease [ID1229]

    Discontinued [GID-TA10196]

    Technology appraisal guidance
    Discontinued

  8. Avacopan for treating anti-neutrophil cytoplasmic antibody-associated vasculitis [ID1178]

    Discontinued [GID-TA10199]

    Technology appraisal guidance
    Discontinued

  9. Elivaldogene autotemcel for treating cerebral adrenoleukodystrophy [ID1284]

    Discontinued [GID-HST10038]

    Highly specialised technologies guidance
    Discontinued

  10. Baricitinib for treating active autoantibody-positive systemic lupus erythematosus [ID3997]

    Discontinued [GID-TA10892]

    Technology appraisal guidance
    Discontinued

  11. Bone loss (therapy-induced) in non-metastatic breast cancer - denosumab [ID83]

    Discontinued [GID-TAG411]

    Technology appraisal guidance
    Discontinued

  12. Pralsetinib for thyroid cancer [ID4018]

    In development [GID-TA10910] Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Pembrolizumab for previously treated oesophageal or gastro-oesophageal junction cancer [ID1357]

    Discontinued [GID-TA10322]

    Technology appraisal guidance
    Discontinued

  14. KRAS mutation testing of tumours in adults with metastatic colorectal cancer (discontinued)

    Discontinued [GID-DT14]

    Diagnostics guidance
    Discontinued

  15. Bevacizumab for the treatment of recurrent glioblastoma multiforme [ID80]

    Discontinued [GID-TAG413]

    Technology appraisal guidance
    Discontinued